LRP3 is a type 1 membrane receptor and member of the low-density lipoprotein receptor family, located on chromosome 19-q13.2 1. While its precise function remains unclear, LRP3 serves as a molecular switch regulating bone marrow stromal cell (hBMSC) lineage commitment: it promotes osteoblast differentiation and inhibits adipocyte differentiation 2. This regulatory role is mediated through the miR-4739/LRP3 axis, with microRNA-4739 targeting the LRP3 3' UTR to suppress osteogenic and promote adipogenic differentiation 2. In neurobiological contexts, LRP3 expression is regulated by ApoER2/reelin signaling and is reduced in Alzheimer's disease-related pathology 3. Notably, LRP3 overexpression decreases amyloid precursor protein (APP) levels and reduces amyloidogenic and non-amyloidogenic APP fragments and Aβ peptides through lysosomal/autophagy-dependent mechanisms 3. Beyond bone and neurological tissues, LRP3 exhibits broad expression across human tissues with highest levels in skeletal muscle and ovary 1, and emerging evidence links LRP3 to candidiasis susceptibility 4 and immune-inflammatory pathways in severe immunotherapy-related cardiac adverse events 5. Despite possessing ligand-binding repeats, LRP3 does not bind VLDL or receptor-associated protein in vitro 1.